Novel therapies against cardiometabolic diseases

CiVi Biopharma is focused on developing innovative oral antisense oligonucleotide therapies, with a particular emphasis on addressing significant unmet medical needs in cardiovascular health. One of their key products, CiVi 008, is a third-generation antisense molecule targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). This molecule is designed to be an oral treatment for hypercholesterolemia and aims to prevent atherosclerotic cardiovascular disease by inhibiting the synthesis of PCSK9 at the mRNA level. By effectively knocking out this protein in the liver, CiVi 008 enhances the uptake of low-density lipoprotein (LDL) cholesterol, thereby reducing harmful cholesterol levels in the bloodstream. The technology behind CiVi 008 offers several advantages over existing monoclonal antibody therapies, including the ability to block both major and minor cellular pathways, which may lead to improved outcomes for patients who do not respond to current treatments.

In addition to CiVi 008, CiVi Biopharma is also developing CiVi 030, an intravenous formulation of iloprost, which serves as a potent vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic properties. This product is being investigated for the treatment of severe frostbite, showcasing the company's commitment to addressing diverse therapeutic areas. The clinical development of these therapies is supported by ongoing studies to validate their mechanisms of action and optimize dosing regimens. Overall, CiVi Biopharma's focus on novel oral therapies and their innovative approaches to existing medical challenges position them as a significant player in the biopharmaceutical landscape.

United States

CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease.  In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.

CiVi Biopharma

Company Details